1406goldM

Commodities jolted on Pfizer vaccine news

Commodities 5 minutes to read

Summary:  Precious metals and energy have reacted strongly in opposite directions after Pfizer and BioNTech earlier today said their coronavirus vaccine was more than 90% effective in preventing Covid-19. Gold slumped by more than 100 dollars while crude oil jumped by close to 10%. We believe both moves set up a mean reversion sooner rather than later.


Precious metals and energy have reacted strongly in opposite directions after Pfizer and BioNTech earlier today said their coronavirus vaccine was more than 90% effective in preventing Covid-19, hailing it a great day for science and humanity.

Coming at a time where Europe and the U.S. are facing a growing number of coronavirus cases, the dramatic shift in focus gave European stocks a major lift while the S&P 500 outperformed the technology heavy, and recently to a certain extent safe haven, Nasdaq composite index

09OLH_vac1

Cyclical commodities depending on growth and demand jumped with crude oil trading higher by 10% while copper extended overnight gains to challenge the October high. Although the timing of a global rollout remains unclear, it is the first major light at the end of the tunnel for parts of the global economy that has been particularly hard hit by the pandemic. Some of these being the airline industry and others depending on our ability to move around. 

Brent crude oil which has traded within a downtrend for the past couple of months broke higher, thereby signaling a return to the range that has prevailed since June. Crude oil and commodities in general do not like equities have the luxury of being able to roll forward expectations as supply and demand need to balance every day. With oil in particularly this means that once it is out of the ground, it needs to be stored or consumed.

While today’s news eventually will set oil on the path to a more sustained, we think the market will struggle to break the September high at $46.50/oz before demand begins to recover. The news may also make it more difficult for OPEC+ to agree on a deal to postpone the planned January production hike. Hedge funds cut bullish oil bets ahead of the U.S. election and with rising Covid-19 cases they were unprepared for today’s news, hence the strong upside reaction through short covering and fresh momentum buying.

09OLH_vac3
Source: Saxo Group

When asked by a journalist earlier today about the sharp fall in gold and silver I answered that the vaccine can kill Covid-19 but not remove the mountain of debt that has been accumulated during the past six months. By saying this we believe that the fundamental reasons for holding gold has not gone away by today’s announcement. With super loose monetary policy in place across the world – China being the exception - we could see an increased risk of a policy mistake being made. If and when that happens, we may see inflation start to make a comeback, thereby supporting demand for protection.

The sustainability of the gold rally after the U.S. election had already started to fade as dollar weakness was not backed up by lower real yields. The news therefore caught the market off guard and once $1930/oz, last week’s breakout level, was breached, long liquidation and fresh short selling helped drive the market sharply lower. In the short-term we will keep a close eye on 10-year U.S. breakevens (+6bp to 1,72%) and real yields (+5 to -0,79). As long real yields continues to rise, gold will struggle. The potential reflation risk emerging from today’s vaccine announcement probably holds the key to the eventual recovery in precious metals.

We do not believe that the gold market rally, let alone silver, has ended with today’s news. For now however the falling knife risk may keep potential buyers sidelined while waiting for the bounce. In terms of support, the first major level is the 38.2% retracement of the March to August rally at $1836/oz. Above that level the current correction can best be described as being a weak one within the existing bull market.

09OLH_vac2
Source: Saxo Group

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.